CA2585268A1 - Methods for lowering hif-1 mediated gene expression - Google Patents

Methods for lowering hif-1 mediated gene expression Download PDF

Info

Publication number
CA2585268A1
CA2585268A1 CA002585268A CA2585268A CA2585268A1 CA 2585268 A1 CA2585268 A1 CA 2585268A1 CA 002585268 A CA002585268 A CA 002585268A CA 2585268 A CA2585268 A CA 2585268A CA 2585268 A1 CA2585268 A1 CA 2585268A1
Authority
CA
Canada
Prior art keywords
hif
cancer
agents
cells
ascorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002585268A
Other languages
English (en)
French (fr)
Inventor
Ajay Verman
Huasheng Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2585268A1 publication Critical patent/CA2585268A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002585268A 2004-10-25 2005-10-25 Methods for lowering hif-1 mediated gene expression Abandoned CA2585268A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62109104P 2004-10-25 2004-10-25
US60/621,091 2004-10-25
PCT/US2005/038317 WO2006047485A2 (en) 2004-10-25 2005-10-25 Methods for lowering hif-1 mediated gene expression

Publications (1)

Publication Number Publication Date
CA2585268A1 true CA2585268A1 (en) 2006-05-04

Family

ID=36228364

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002585268A Abandoned CA2585268A1 (en) 2004-10-25 2005-10-25 Methods for lowering hif-1 mediated gene expression

Country Status (6)

Country Link
US (1) US20080045463A1 (enExample)
EP (1) EP1814570A2 (enExample)
JP (1) JP2008517943A (enExample)
AU (1) AU2005299482A1 (enExample)
CA (1) CA2585268A1 (enExample)
WO (1) WO2006047485A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010024908A1 (en) * 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
WO2012082765A2 (en) * 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
WO2012135397A2 (en) * 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
EP3113766B1 (en) * 2014-03-05 2021-04-07 Evan C. Unger Fractionated radiotherapy and chemotherapy with an oxygen therapeutic
JP7160683B2 (ja) * 2016-04-29 2022-10-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 術後癒着の予防及び治療のための方法及び組成物
JP7280470B2 (ja) * 2019-11-29 2023-05-24 慶應義塾 特定アミノ酸またはアミノ酸様物質による低酸素応答制御
CA3218944A1 (en) * 2021-05-16 2022-11-24 Slavica TUDZAROVA-TRAJKOVSKA Methods and compositions for treating cardiovascular disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US6566088B1 (en) * 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
EP1709175A2 (en) * 2003-12-03 2006-10-11 Corgentech, Inc. Hif oligonucleotide decoy molecules

Also Published As

Publication number Publication date
WO2006047485A3 (en) 2008-03-06
WO2006047485A8 (en) 2007-06-14
EP1814570A2 (en) 2007-08-08
US20080045463A1 (en) 2008-02-21
JP2008517943A (ja) 2008-05-29
AU2005299482A1 (en) 2006-05-04
WO2006047485A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
Zhong et al. NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors
Lu et al. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1
Jewell et al. Induction of HIF–1α in response to hypoxia is instantaneous
AU2012315586B2 (en) Aromatic-cationic peptides and methods for using same
US10987345B2 (en) Method for assessing the efficacy of IMiDs and composition or combination for use in treating IMiD sensitive diseases
WO2013152041A1 (en) Targeting senescent and cancer cells for selective killing by interference with foxo4
Gu et al. Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation
WO2013152038A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
Deng et al. GPA peptide enhances Nur77 expression in intestinal epithelial cells to exert a protective effect against DSS‐induced colitis
US20090227521A1 (en) Use of compounds in the treatment of ischemia and neurodegeneration
CN102137680A (zh) 用apoe肽治疗癌症的方法
EP1967526A1 (en) Inhibitor of TGF-ß activation reaction
US20080045463A1 (en) Methods For Lowering Hif-1 Mediated Gene Expression
EP3738603A1 (en) Ntcp inhibitor
JP2007505860A (ja) ヒストンデアセチラーゼ阻害剤と細胞死受容体リガンドの組み合わせ
CN113209303A (zh) Wwp1通过溶酶体途径降解癌蛋白muc1抑制肿瘤及其应用
WO2025167587A1 (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
Rossi et al. The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy
US20060083742A1 (en) Prenyl-electrostatic switch, and methods of use
JP2008230977A (ja) ニチジンを成分とする抗癌剤、および該抗癌剤の感受性増強剤
US20240382561A1 (en) Glucoregulatory compound, composition and uses thereof
Shi et al. Kynurenine analog 3-HAA is a ligand for transcription factor YY1
US20120245078A1 (en) Means and methods for treating ischemic conditions
EP1661990A1 (en) Polypeptide specific to liver cancer, polynucleotide encoding the polypeptide and rna molecule inhibiting the expression of the polypeptide
Ginsberg et al. Laura R. de la Ballina1, 2, Sara Cano-Crespo1, 3, Elena González-Muñoz1, 4, Susanna Bial1, 3, Soline Estrach2, Laurence Cailleteau2, Floriane Tissot2, Hannelore Daniel5, Antonio Zorzano1, 6, Mark H.

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20101025